Paion Past Earnings Performance

Past criteria checks 0/6

Paion's earnings have been declining at an average annual rate of -1074.5%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 48.5% per year.

Key information

-1,074.5%

Earnings growth rate

-1,070.2%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate-48.5%
Return on equityn/a
Net Margin-134.1%
Last Earnings Update30 Jun 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Paion makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:PA8K Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2315-20205
31 Mar 2324-10216
31 Dec 2233-1216
30 Sep 2227-3226
30 Jun 2229-2215
31 Mar 2218-12215
31 Dec 217-22205
30 Sep 216-20156
30 Jun 2120-2137
31 Mar 2118-1108
31 Dec 20202810
30 Sep 20202712
30 Jun 204-14613
31 Mar 2012-5614
31 Dec 198-7513
30 Sep 1910-5413
30 Jun 1910-3412
31 Mar 193-10412
31 Dec 183-10312
30 Sep 181-12413
30 Jun 182-13414
31 Mar 184-13417
31 Dec 176-12418
30 Sep 177-13421
30 Jun 178-13421
31 Mar 176-16521
31 Dec 164-20523
30 Sep 162-24525
30 Jun 160-30630
31 Mar 160-30630
31 Dec 150-28629
30 Sep 152-23626
30 Jun 152-17519
31 Mar 153-12416
31 Dec 143-9412
30 Sep 145-548
30 Jun 145-437
31 Mar 143-435
31 Dec 134-235

Quality Earnings: PA8K is currently unprofitable.

Growing Profit Margin: PA8K is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if PA8K's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare PA8K's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PA8K is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: PA8K's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 18:40
End of Day Share Price 2024/12/20 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Paion AG is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John SavinEdison Investment Research
Simon ScholesFirst Berlin Equity Research GmbH
Christian EhmannFMR - Frankfurt Main Research AG